Core Viewpoint - The biotechnology sector in Hong Kong is experiencing a surge, with companies like Ai Mei Vaccine gaining significant attention due to their stable performance and innovative technologies [1] Group 1: Company Performance - Ai Mei Vaccine reported steady revenue growth for the first half of 2025, with key innovative products nearing market launch, leading to expectations of improved performance and valuation [1][2] - The company has four major innovative products entering the market, including the 13-valent pneumococcal conjugate vaccine, which has a significant market potential in China, projected to exceed RMB 20 billion by 2030 [2][3] Group 2: Product Development - Ai Mei Vaccine is advancing in the rabies vaccine sector with multiple products, including a serum-free rabies vaccine and an mRNA rabies vaccine, positioning itself as a leader in a market expected to reach RMB 20 billion by 2030 [3] - The company holds 20 vaccine candidates in development across 12 disease areas, with 23 clinical approvals and 24 clinical trials ongoing, including seven innovative vaccines [3] Group 3: Market Potential and Valuation - The 13-valent pneumococcal conjugate vaccine is anticipated to capture a significant market share, with a penetration rate in China estimated at 25.9%, compared to over 80% in the U.S., indicating substantial growth opportunities [2] - DBS Bank's report suggests that Ai Mei Vaccine's current stock price is at the lower end of its peers' valuation range, with a projected fair target price of HKD 8.3 per share by 2026, indicating a potential upside of nearly 600% [4]